Details
Category: Volume 11 Issue 03 March 2023
Hits: 360

Title: GIST (Gastrointestinal Stromal Tumours): A Clinical Study of 32 Cases

Authors: Dr Anant S. Ramani, Dr Guruprasad Huske, Dr Vishal Sardesai

 DOI: https://dx.doi.org/10.18535/jmscr/v11i3.15

Abstract

Background: GIST (Gastrointestinal stromal tumours) are rare mesenchymal tumours of the Gastrointestinal tract accounting for 3% of Gastrointestinal malignancies and overexpress C-kit proteins CD117, CD34 and PGDFRA.

Methods: This clinical study was done on 32 patients of GIST in our institution over a period of 7 years with a minimum follow up of 5 years to study the demographics, presentation, management and prognostic criteria of GISTs.

Results: The majority of the tumours originated from stomach and small bowel, a few from Esophagus, Rectum and mesentery. GIST predominantly affected the elderly. CT scan and endoscopy were the main diagnostic modalities with final confirmation by Histopathology and immunohistochemistry. Most of the patients underwent surgical resection followed by oral imatinib.

Conclusion: GIST have unpredictable behavior. The malignant potential of the disease depends on the site, size and mitotic index of the tumour. Surgery with imatinib is the main treatment option in absence of response of GIST to Radio or chemotherapy.

Keywords: Gastrointestinal stromal tumours, Imatinibmesylate, enbloc resection.

References

  1. Norman Machado, Pradeep Chopra, Ibrahim Hassan, Hani Al-Qadhi. J. Pancreas (Online) 2011 Mar 9:12(2):194-199
  2. Bucher P, Villiger P, Egger JF, Buhler LH, Morel P. Management of gastrointestinal stromal tumours: From diagnosis to treatment. Swiss Med wkly 2004;134: 145-53.
  3. Antonescu CR, Sommer G, Sarran L et al .Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumours. Clin Cancer Res.2003 Aug 15;9(9):3329-37.
  4. Ueyama T, Guo KJ.A clinicopathological and Immunohistological study of GIST. CANCER 1992 Feb;69(4):947-55.
  5. Dematto RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumours: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-58.
  6. Gier T, Hjortur G. Gastrointestinal stromal tumours in Iceland: The Iceland GIST studya population based incidence and pathological risk stratification study.Int J Cancer 117; 289-93.
  7. Nivedita Singh, Gastrointestinal stromal tumours: A clinicopathological and immunohistochemical study. Int J cur rev; Vol.8,Issue 18.Sept.2016.
  8. Mukul Vij, Vinita Agrawal, Rakesh Pandey. Malignant Extra-Gastrointestinal stromal tumourn of the Pancreas. A case report and Review of Literature.J. Pancreas (Online) 2011 March 9: 12(2): 200-204.
  9. Yu Nu Kang, Hye Ra. Clinicopatholigical and Immunohistochemical features of GIST.Cancer Res Tret 2010: 42(3), 135-143.
  10. Miettinem M, Kopczynski J, Makhlouf HR, Sarlomo-Rikala M, Gyorffy H, Burke A et al. gastrointestinal stromal tumours, intramural leiomyomas and leiomyosarcomas in the duodenum. A clinicopathological, immunohistochemical and molecular genetic study of 167 cases. Am J SurgPathol 2003;27:625-41.
  11. Chung JC, Chu CW, Cho GS, Shin EJ, Lim CW, Kim HC, Song OP. Management and outcome of Gastrointestinal stromal tumours of the duodenum. J Gastrontest Surg 2010;14:880-3.
  12. Mennigen R, Wolters HH, Schulte B, Pelster FW. Segmental resection of the duodenum for gastrointestinal stromal tumour (GIST).World J SurgOncol 2008;6:105.
  13. Gervaz P, Huber O, Morel P. Surgical management of gastrointestinal stromal tumours.Br J Surg 2009;96:567-78.
  14. Ghanem N, Altehoefer C, Furtwangler A, Winterer J, Schafer O, Springer Oetal. Computed tomography in gastrointestinal stromal tumour. Eur Radiol 2003;13:1669-78.
  15. Sandrasegaran K, Rajesh A, Rushing DA, Rydberg J, Akisik FM, Henley JD. Gastrointestinal stromal tumour. CT & MRI finding. Eur Radiol 2005;15:1407-14.
  16. Gold JS,Van der Zwan SM, Gonen M, Maki RG, Singer S, Brennan MF. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol 2007;14:134-42.
  17. Francisco Eduardo Silva,Ana Claudia Leita da Silva.The use of 2nd generation Protein kinase Inhibitors in patients with Gastrointestinal stromal tumours with failure to the treatment with Imatinib. Open Acess J Surg.2017;3(3):555614.

Corresponding Author

Dr Anant S. Ramani

Associate Professor of Surgery, Dept. of Surgery, Goa Medical College, Bambolim - Goa, Pin: 403502